Wall Street analysts predict that Spero Therapeutics Inc (NASDAQ:SPRO) will post sales of $400,000.00 for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Spero Therapeutics’ earnings. The highest sales estimate is $600,000.00 and the lowest is $200,000.00. The business is scheduled to report its next quarterly earnings results on Thursday, April 5th.
According to Zacks, analysts expect that Spero Therapeutics will report full year sales of $400,000.00 for the current financial year, with estimates ranging from $1.19 million to $1.58 million. For the next fiscal year, analysts forecast that the company will post sales of $8.20 million per share. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Spero Therapeutics.
Several research analysts have commented on the stock. Oppenheimer set a $30.00 target price on shares of Spero Therapeutics and gave the stock a “buy” rating in a report on Thursday, January 11th. Zacks Investment Research cut shares of Spero Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. ValuEngine upgraded shares of Spero Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Finally, Cantor Fitzgerald assumed coverage on shares of Spero Therapeutics in a report on Thursday, February 8th. They issued an “overweight” rating and a $27.00 target price for the company. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $24.25.
Several institutional investors and hedge funds have recently made changes to their positions in the business. Dean Capital Investments Management LLC acquired a new stake in shares of Spero Therapeutics during the fourth quarter worth approximately $118,000. Atlas Venture Associates IX LLC acquired a new stake in shares of Spero Therapeutics during the fourth quarter worth approximately $16,179,000. California Public Employees Retirement System acquired a new stake in shares of Spero Therapeutics during the fourth quarter worth approximately $294,000. BlackRock Inc. acquired a new stake in shares of Spero Therapeutics during the fourth quarter worth approximately $2,830,000. Finally, Artal Group S.A. acquired a new stake in shares of Spero Therapeutics during the fourth quarter worth approximately $4,113,000. Institutional investors own 46.28% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was first published by WKRB News and is owned by of WKRB News. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://www.wkrb13.com/2018/04/01/400000-00-in-sales-expected-for-spero-therapeutics-inc-spro-this-quarter.html.
About Spero Therapeutics
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. It is developing SPR994, an oral carbapenem-class antibiotic for use in adults to treat MDR gram-negative infections; SPR741 that has completed Phase I clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic that is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.